Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Gamida Cell Ltd. GMDA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • IL • USD

SharesGrow Score
29/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Gamida Cell Ltd. (GMDA) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 7 Buy, 1 Hold.

GMDA Analyst Ratings

Buy
8
Ratings
7 Buy
1 Hold
Based on 8 analysts giving stock ratings to Gamida Cell Ltd. in the past 3 months
Rating breakdown
Buy
7 88%
Hold
1 13%
88%
Buy
7 analysts
13%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 IBRX
IBRX
ImmunityBio, Inc.
$7.78
+2.37%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 ARDX
ARDX
Ardelyx, Inc.
$6.30
-0.47%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.82
+4.95%
 LXRX
LXRX
Lexicon Pharmaceuticals, Inc.
$1.86
+6.29%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message